Reporting Standards for Medical AI

“The model achieved an area under the curve of 0.92” sounds impressive, but it leaves most clinical questions unanswered. Which patients were represented? Was the test set truly separate? What outcome served as truth? Was the number measured at one hospital or several? At which threshold does the tool act, and what happens to false positives, false negatives, workload, and patient care?

Medical AI reporting standards turn a performance claim into something readers can inspect. Different guidelines apply to prediction models, diagnostic accuracy, randomized trials, imaging, and early use in clinical workflows. Their common purpose is not to award a quality badge. It is to disclose enough about the claim, data, model, evaluation, and limits for you to judge fitness for the stated use.

Key points#

• Begin with intended use: population, setting, user, input, output, and decision.
• Describe data provenance, eligibility, labels, missingness, timing, and dataset splits.
• Report calibration and threshold-specific consequences, not discrimination alone.
• Separate technical validation from clinical utility and workflow evaluation.
• Identify the exact model version, human role, failure conditions, and availability of materials.

Choose the guideline by the study question#

There is no single universal medical AI checklist. TRIPOD+AI applies to studies developing or evaluating multivariable prediction models, whether statistical or machine learned, while STARD-AI, published in 2025, applies when an AI system is evaluated as an index test against a reference standard for diagnostic accuracy.

CONSORT-AI extends randomized trial reporting when an AI intervention is part of the trial. Its protocol companion is SPIRIT-AI. DECIDE-AI focuses on early-stage, small-scale clinical evaluation of AI decision-support systems in real workflows, including human factors and safety. CLAIM provides imaging-specific guidance and was updated in 2024.

One project may need more than one guideline. An imaging model-development paper may use TRIPOD+AI and CLAIM. A later diagnostic accuracy study may use STARD-AI and CLAIM. A randomized impact trial may use CONSORT 2025 plus CONSORT-AI. Authors should name the versions used and explain their fit rather than treating “AI reporting guideline followed” as sufficient.

Intended use anchors every metric#

A report should state what the system is intended to do, for whom, and where. It should state when, with which inputs, used by whom, and to inform what decision. “Detects deterioration” is incomplete. A checkable claim might specify that a locked model estimates 24-hour deterioration risk for adults admitted to particular wards, using variables available by a defined time, and alerts a named clinical role for review.

That statement determines appropriate participants, outcomes, comparators, thresholds, and workflow. It also prevents scope inflation. Performance in adults at tertiary hospitals does not establish performance in children, outpatient clinics, or smaller hospitals, and a risk score is not automatically a diagnostic device, and a diagnostic classifier is not automatically evidence that care improves.

The report should distinguish intended users from affected people: a system may be operated by a radiologist, nurse, pharmacist, or administrator while changing decisions for patients who never see its interface. Both groups matter when workflow and harm are assessed.

Data provenance is part of the model description#

You need to know where the data came from, with the collection dates, sites, devices, eligibility criteria, sampling method, and whether the records were retrospective or prospective, plus counts before and after exclusions, a description of missing data, and a participant flow that preserves denominators. All of it, or the denominator is a guess.

Labels need equal scrutiny. Who assigned the reference outcome, using what information, under what instructions, and with what adjudication? If the outcome was extracted from billing codes or a later clinical decision, the report should say so, because a model can reproduce documentation or care patterns rather than the underlying condition.

Dataset splitting must be described at the unit where leakage can occur. Images from one patient, repeated admissions, or related samples should not appear across development and test sets when that would let the model recognize the source; a random row split can look excellent while testing near-duplicates.

Time and site separation provide stronger challenges. A temporal test asks whether the model survives changed practice and prevalence. A geographic test asks whether it transfers to different populations, equipment, and workflows. Calling a held-out subset from the same source “external validation” obscures the distinction.

Preprocessing also belongs in the report: normalization, feature construction, and imputation. The report covers data augmentation, handling of outliers, and any manual review. Choices made before model fitting can leak outcome information just as easily as the algorithm can.

Describe the model so the evaluated object is identifiable#

The algorithm family alone is not enough. A report should identify inputs, architecture or model form, and training objective. It should identify tuning process, stopping rule, and software environment. It should identify pretrained components and the final decision threshold. If a foundation model or external service is used, record the provider and exact version or access date.

You also need to know whether the model was locked during evaluation. Repeatedly tuning against the test set converts it into development data. If updates occurred, the report should explain their timing and preserve a final untouched evaluation.

Code, weights, prompts, feature definitions, and data may not all be shareable. Privacy, cybersecurity, intellectual property, or licensing can prevent it. Limitations can be legitimate, but the report should state what is available, to whom, under what conditions, and what cannot be reproduced as a result.

Performance requires more than one headline number#

Discrimination measures how well a system ranks cases relative to noncases. AUROC can be useful, but it may stay high even when most of the positive predictions you would act on are wrong in a low-prevalence setting. Precision-recall curves and positive and negative predictive values help reveal consequences tied to prevalence.

Calibration asks whether predicted probabilities match observed frequencies. A model that ranks well but systematically reports risks twice as high as observed can mislead decisions. Calibration plots, intercept, slope, and uncertainty should be reported in the evaluation population.

Threshold-specific results translate scores into action. Sensitivity, specificity, and predictive values should be shown at prespecified operating points. So should false alerts per relevant unit, numbers flagged, and decision consequences. Confidence intervals matter. Comparisons should use the same participants and reference standard.

Subgroup reporting should be clinically and socially justified, sufficiently powered, and accompanied by uncertainty. A table of point estimates for many small groups can create false reassurance or false alarms. Differences may reflect prevalence, label quality, or access patterns. They may reflect site or measurement, not an inherent group trait.

Technical accuracy is not clinical utility#

A retrospective test can show association with a recorded outcome. It cannot by itself show that clinicians will use the result appropriately, that decisions improve, or that benefits outweigh harms. Workflow changes can create automation bias, alert fatigue, delays, duplicated work, or new inequities.

Early prospective studies should report how users received outputs, what explanations were shown, when users accepted or overrode recommendations, what training they received, and what safety events occurred. DECIDE-AI is useful here because it treats the human-system interaction as part of the intervention. A randomized impact evaluation may come later and compare AI-assisted care with an appropriate control, and CONSORT-AI asks for details specific to the system and its use, but the ordinary trial questions still apply: allocation, missing outcomes, prespecification, effect estimates, harms, and relevance.

Failure conditions and uncertainty belong in the main claim#

Every model has boundaries. Reports will tell you about known poor-quality inputs, unsupported populations, and uncommon presentations. They will tell you about device incompatibilities, workflow dependencies, and conditions that trigger abstention or human escalation. Examples of incorrect predictions can reveal error patterns that aggregate metrics hide.

Uncertainty should be operational. If a score is unstable when an input is missing or when prevalence changes, users need to know. A confidence score is not automatically calibrated uncertainty. Reports should explain what uncertainty measure represents and how it affects action.

Post-deployment monitoring is a separate lifecycle responsibility, but reporting should prepare for it. It should name the baseline data distribution, performance targets, and safety indicators. It should name the version and change-control plan. Without an identifiable baseline, drift cannot be distinguished from ordinary variation.

Appraisal limits#

Complete reporting does not prove unbiased data, a correct reference standard, or transportability. It does not prove benefit, regulatory compliance, or cybersecurity. And checklists can be applied mechanically. An author can disclose a weak split or a poorly chosen threshold perfectly, and you will still have to notice that it is weak.

Publication limits may restrict technical detail, but durable supplements and repositories can help. Proprietary restrictions reduce what you can verify from outside and should be treated as an evidence limitation, not hidden behind a general confidentiality statement.

Guidelines evolve. As of July 15, 2026, STARD-AI is an important current addition to the reporting landscape. Authors and reviewers should check the EQUATOR library for current versions and relevant extensions when a study is submitted.